The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab

作者：Jing Yan, Jun Wu, Run-Qiu Wang, Pin Meng, Ailing Liu, Yonghong Xu · 发表于：Frontiers in Medicine · 年份：2025 · DOI：10.3389/fmed.2025.1524307 · 被引用次数：4 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Inflammatory Bowel Disease、Inflammation biomarkers and pathways

Background Vedolizumab (VDZ), a novel biologic targeting α4β7 integrin, is safe and effective for the treatment of patients with ulcerative colitis (UC). The objective of this study was to compare the potential of the Platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) in predicting clinical remission and treatment failure in patients with moderate-to-severe UC on VDZ therapy and to explore the risk factors for treatment failure. Methods Seventy-four UC patients treated with VDZ at our institution between December 1, 2020, and October 1, 2023, who had medical records were included in this study. We retrospectively collected baseline NLR, PLR, and SII values and assessed the predictive ability of the three indices for clinical remission and treatment failure using the receiver operating characteristic (ROC) curves. Results Patients in the severe group ( n = 47) had significantly higher baseline PLR and SII values than those in the moderate group ( n = 27) ( p < 0.05). Patients with MES3 had significantly higher PLR and SII values than patients with MES2 ( p < 0.05). At 14 weeks after VDZ treatment, 28 patients obtained steroid-free clinical remission, whereas 46 did not. The area under the ROC curve (AUC) for SII was 0.659 for predicting clinical remission and exhibited the best predictive ability. Of the 52 patients who achieved long-term remission, 35 patients responded consistently to VDZ, wher...